2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate
Gadodiamide
CAS: 131410-48-5
Molecular Formula: C16H26GdN5O8
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate - Names and Identifiers
| Name | Gadodiamide |
| Synonyms | S-041 Omniscan Gd-DTPA-BMA GADODIAMIDE Gadodiamide GADODIAMIDE (500 MG) 2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate gadolinium 2-[bis[2-(carboxylatomethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetate [5,8-Bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraaza-tridecan-13-oato(3-)]gadolinium gadolinium 5,8-bis(carboxylatomethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oate (non-preferred name) |
| CAS | 131410-48-5 |
| InChI | InChI=1/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3 |
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate - Physico-chemical Properties
| Molecular Formula | C16H26GdN5O8 |
| Molar Mass | 573.658 |
| Melting Point | >300°C (dec.) |
| Boling Point | 769.1°C at 760 mmHg |
| Flash Point | 419°C |
| Solubility | Methanol (Slightly, Heated), Water (Slightly) |
| Vapor Presure | 6.54E-26mmHg at 25°C |
| Appearance | Solid |
| Color | White to Off-White |
| Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
| Physical and Chemical Properties | Acute toxicity LD50 mice (mmol/kg):14 I. V. Berbamine for injection: C16H28GdN5O9? C16H26CaN5NaO8. [131410-51-0]. Viscosity (Pa? s):0.002(20 degrees C),0.0014(37 degrees C). D20 1.13. Partition coefficient (butanol/water):-2.1. Acute toxicity LD50 mice (mmol/kg):34 intravenously. |
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate - Risk and Safety
| HS Code | 2846909000 |
| Toxicity | LD50 i.v. in mice: 14 mmol/kg (Chang) |
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.743 ml | 8.716 ml | 17.432 ml |
| 5 mM | 0.349 ml | 1.743 ml | 3.486 ml |
| 10 mM | 0.174 ml | 0.872 ml | 1.743 ml |
| 5 mM | 0.035 ml | 0.174 ml | 0.349 ml |
Last Update：2024-01-02 23:10:35
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate - Reference Information
| application | gd diamine is suitable for magnetic resonance imaging of central nervous system (brain and spinal cord), abdomen, chest, pelvic cavity and limbs. The required dose must be given in one intravenous injection. In order to ensure complete injection, NS can be used to flush the intravenous catheter. |
| pharmacological effects | gd diamine is a non-ionic paramagnetic water-soluble contrast agent. After injection, gd diamine is quickly distributed to the extracellular fluid, and its distribution is equal to the amount of water in the extracellular fluid. Its distribution half-life is 4 minutes, and the excretion half-life is about 70 minutes. Gaddiamine is excreted through the kidneys by glomerular filtration. |
| pharmacokinetics | after injection, this product is quickly distributed to the extracellular fluid, and its distribution amount is equal to the amount of water in the extracellular fluid. The distribution half-life is 4 minutes, and the excretion half-life is about 70 minutes. The prolongation of excretion half-life in patients with renal insufficiency (GFR<30ml/min) is inversely proportional to GFR value. This product is excreted through the kidneys through glomerular filtration. For patients with normal renal function, about 85% of the injection volume is excreted in urine after 4 hours of injection. After 24 hours of intravenous injection, 95% ~ 98% of the injection was excreted. The renal clearance rate and total clearance rate of this product are almost the same, similar to other drugs that are mainly filtered and excreted through the glomerulus. No dose-related pharmacokinetic changes were found when 0.1~0.3mmol/kg was injected. No metabolites were detected and no protein binding was observed. |
| adverse reactions | adverse reactions are mostly short-lived and mild. Occasionally, there is discomfort at the injection site, accompanied by heat, cold, swelling and pain. Dizziness, nausea, headache, loss of smell and taste, vomiting, drowsiness, paresthesia, visual impairment, diarrhea, anxiety, dyspnea, chest pain, tachycardia, tremor, arthralgia or allergic symptoms such as urticaria, skin itching or throat irritation are rare. Allergic reactions may occur. |
| use | MRI contrast agent. |
| production method | is obtained from the complexation of acid and cadmium. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 21:00:56
![2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate](http://res.chembk.com/assets/str/2d/1/13/131410-48-5.png)
Supplier List
Product Name: Gadodiamide Visit Supplier Webpage Request for quotation
CAS: 131410-48-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 131410-48-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Gadodiamide Visit Supplier Webpage Request for quotation
CAS: 131410-48-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 131410-48-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History